RT Journal Article
SR Electronic
T1 Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 60
OP 63
DO 10.7497/j.issn.2095-3941.2014.0025
VO 12
IS 1
A1 Hingorani, Mohan
A1 Dixit, Sanjay
A1 Pugazhenthi, Pattu
A1 Hawkyard, Simon
A1 Robertson, Andrew
A1 Khafagy, Richard
YR 2015
UL http://www.cancerbiomed.org/content/12/1/60.abstract
AB Palliative radiotherapy (pRT) is primarily employed for palliation of bone pain in patients with castrate-resistant prostate cancer (CRPC). However, evidence that pRT influences prostate-specific antigen response in patients with CRPC on systemic therapy is lacking. We describe three cases of CRPC progressing after treatment with docetaxel (n=2) and abiraterone (n=1), who responded unusually after pRT for bone pain with the development of a significant biochemical response and restoration of response to systemic therapy. The possibility of pRT influencing metastatic disease in CRPC has not been previously reported, and raises the possibility of radiation-induced modulation of anti-tumor immune response mechanisms that may play a role in the restoration of response to systemic treatment.